Review



goat polyclonal anti cxcl13 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems goat polyclonal anti cxcl13 antibody
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Goat Polyclonal Anti Cxcl13 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 75 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+Antibody/pmc13106335-70-10-15
    Average 93 stars, based on 75 article reviews
    goat polyclonal anti cxcl13 antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases"

    Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2026.1804103

    CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Figure Legend Snippet: CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.

    Techniques Used: Expressing, Whisker Assay, Standard Deviation

    CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.
    Figure Legend Snippet: CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.

    Techniques Used: Immunohistochemical staining, Expressing, Staining

    Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.
    Figure Legend Snippet: Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.

    Techniques Used: Clinical Proteomics, Diagnostic Assay, Whisker Assay, Sampling, MANN-WHITNEY, Derivative Assay

    Related Articles

    Immunofluorescence:

    Article Title: Fate mapping and scRNA sequencing reveal origin and diversity of lymph node stromal precursors.
    Article Snippet: For staining with anti-a-SMA antibody an additional 20 min incubation at RT with M.O.M. (#MKB-2213-1, Vector Laboratories) before blocking buffer was performed; instead for staining with anti-CD35 antibody an additional incubation at RT with Avidin/Biotin Blocking Kit (#SP-2001, Vector Laboratories) before blocking buffer was done. .. Immunofluorescence staining with amplification of signal using TSA Plus fluorescein kit (#NEL701A001KT, AKOYA Biosciences) was used for the following antibodies: anti-CCL21 (#AF457, R&D systems, 1:200), anti-CD34 (#Ab81289, Abcam, 1:2000), anti-CXCL13 (#AF470, R&D Systems, 1:100), anti- Ly6A (#Ab51317, Abcam, 1:5000), anti-MAdCAM1 (#120706, Biolegend, 1:10.000), anti-GP38 (#14-5381-82, eBioscience, 1:500). ..

    Article Title: Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients
    Article Snippet: .. Immunofluorescence staining of biopsy tissues was performed as previously described.49 The following primary antibodies were used in these experiments: anti-CD3« (catalog ab5690; Abcam, Cambridge, UK), antiCD20 (catalog 14-0202; eBioscience, San Diego, CA), Ki67 (catalog ab16667; Abcam), anti-CD21 (catalog ab75985; Abcam, and catalog MA5-11417; Thermo Fisher Scientific, Waltham, MA), anti-CD45 (catalog 14-9457; eBioscience), anti-p75NTR (catalog AF1157; R&D Systems, Minneapolis, MN), and anti-CXCL13 (catalog AF801; R&D Systems). ..

    Staining:

    Article Title: Fate mapping and scRNA sequencing reveal origin and diversity of lymph node stromal precursors.
    Article Snippet: For staining with anti-a-SMA antibody an additional 20 min incubation at RT with M.O.M. (#MKB-2213-1, Vector Laboratories) before blocking buffer was performed; instead for staining with anti-CD35 antibody an additional incubation at RT with Avidin/Biotin Blocking Kit (#SP-2001, Vector Laboratories) before blocking buffer was done. .. Immunofluorescence staining with amplification of signal using TSA Plus fluorescein kit (#NEL701A001KT, AKOYA Biosciences) was used for the following antibodies: anti-CCL21 (#AF457, R&D systems, 1:200), anti-CD34 (#Ab81289, Abcam, 1:2000), anti-CXCL13 (#AF470, R&D Systems, 1:100), anti- Ly6A (#Ab51317, Abcam, 1:5000), anti-MAdCAM1 (#120706, Biolegend, 1:10.000), anti-GP38 (#14-5381-82, eBioscience, 1:500). ..

    Article Title: Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients
    Article Snippet: .. Immunofluorescence staining of biopsy tissues was performed as previously described.49 The following primary antibodies were used in these experiments: anti-CD3« (catalog ab5690; Abcam, Cambridge, UK), antiCD20 (catalog 14-0202; eBioscience, San Diego, CA), Ki67 (catalog ab16667; Abcam), anti-CD21 (catalog ab75985; Abcam, and catalog MA5-11417; Thermo Fisher Scientific, Waltham, MA), anti-CD45 (catalog 14-9457; eBioscience), anti-p75NTR (catalog AF1157; R&D Systems, Minneapolis, MN), and anti-CXCL13 (catalog AF801; R&D Systems). ..

    Amplification:

    Article Title: Fate mapping and scRNA sequencing reveal origin and diversity of lymph node stromal precursors.
    Article Snippet: For staining with anti-a-SMA antibody an additional 20 min incubation at RT with M.O.M. (#MKB-2213-1, Vector Laboratories) before blocking buffer was performed; instead for staining with anti-CD35 antibody an additional incubation at RT with Avidin/Biotin Blocking Kit (#SP-2001, Vector Laboratories) before blocking buffer was done. .. Immunofluorescence staining with amplification of signal using TSA Plus fluorescein kit (#NEL701A001KT, AKOYA Biosciences) was used for the following antibodies: anti-CCL21 (#AF457, R&D systems, 1:200), anti-CD34 (#Ab81289, Abcam, 1:2000), anti-CXCL13 (#AF470, R&D Systems, 1:100), anti- Ly6A (#Ab51317, Abcam, 1:5000), anti-MAdCAM1 (#120706, Biolegend, 1:10.000), anti-GP38 (#14-5381-82, eBioscience, 1:500). ..

    Immunohistochemistry:

    Article Title: Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21
    Article Snippet: .. For immunohistochemistry, human tumor sections were incubated with anti-CD4 (1:200, ab133616, Abcam), anti-CXCL13 (1:200, AF801, R&D), anti-IL-21(1:200, ab5978, Abcam), anti-CD8 (1:300, ab237709, Abcam), and anti-CD20 (1:300, ab78237, Abcam) antibodies; mouse tumor sections were incubated with anti-CD8 (1:500, ab209775, Abcam), anti-CD20 (1:500, ab122788, Abcam), and anti-CD138 (1:200, ab181789, Abcam) antibodies. .. For immunofluorescence, human tumor sections were incubated with anti-CD4 (1:200, ab133616, Abcam), anti-CXCR5 (1:200, ab46218, Abcam), anti-PD-1 (1:200, ab53587, Abcam), anti-CXCL13 (1:50, AF801, R&D), anti-IL-21(1:100, ab5978, Abcam), anti-CD8(1:500, ab237709, Abcam), and anti-CD20 (1:200, ab78237, Abcam) antibodies.

    Incubation:

    Article Title: Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21
    Article Snippet: .. For immunohistochemistry, human tumor sections were incubated with anti-CD4 (1:200, ab133616, Abcam), anti-CXCL13 (1:200, AF801, R&D), anti-IL-21(1:200, ab5978, Abcam), anti-CD8 (1:300, ab237709, Abcam), and anti-CD20 (1:300, ab78237, Abcam) antibodies; mouse tumor sections were incubated with anti-CD8 (1:500, ab209775, Abcam), anti-CD20 (1:500, ab122788, Abcam), and anti-CD138 (1:200, ab181789, Abcam) antibodies. .. For immunofluorescence, human tumor sections were incubated with anti-CD4 (1:200, ab133616, Abcam), anti-CXCR5 (1:200, ab46218, Abcam), anti-PD-1 (1:200, ab53587, Abcam), anti-CXCL13 (1:50, AF801, R&D), anti-IL-21(1:100, ab5978, Abcam), anti-CD8(1:500, ab237709, Abcam), and anti-CD20 (1:200, ab78237, Abcam) antibodies.



    Similar Products

    anti cxcl13  (Vaccinex Inc)
    86
    Vaccinex Inc anti cxcl13
    Anti Cxcl13, supplied by Vaccinex Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/anti+cxcl13/pm42030157-323-0-7
    Average 86 stars, based on 1 article reviews
    anti cxcl13 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    goat polyclonal anti cxcl13 antibody  (R&D Systems)
    93
    R&D Systems goat polyclonal anti cxcl13 antibody
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Goat Polyclonal Anti Cxcl13 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+Antibody/pmc13106335-70-10-15
    Average 93 stars, based on 1 article reviews
    goat polyclonal anti cxcl13 antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti cxcl13  (R&D Systems)
    92
    R&D Systems anti cxcl13
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Anti Cxcl13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+Antibody/pm41957358-132-12-16
    Average 92 stars, based on 1 article reviews
    anti cxcl13 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    anti cxcl13 pe  (R&D Systems)
    94
    R&D Systems anti cxcl13 pe
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Anti Cxcl13 Pe, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+PE-conjugated+Antibody/pmc13041753-228-19-20
    Average 94 stars, based on 1 article reviews
    anti cxcl13 pe - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cxcl13  (Santa Cruz Biotechnology)
    91
    Santa Cruz Biotechnology cxcl13
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Cxcl13, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/BLC+Antibody/pm41904200-207-13-16
    Average 91 stars, based on 1 article reviews
    cxcl13 - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    cxcl13 blc bca 1  (R&D Systems)
    94
    R&D Systems cxcl13 blc bca 1
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Cxcl13 Blc Bca 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/Human+CXCL13%2FBLC%2FBCA-1+APC-conjugated+Antibody/pmc13086164-424-31-32
    Average 94 stars, based on 1 article reviews
    cxcl13 blc bca 1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rabbit anti cxcl13 recombinant multiclonal antibody  (Proteintech)
    93
    Proteintech rabbit anti cxcl13 recombinant multiclonal antibody
    <t>CXCL13</t> mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.
    Rabbit Anti Cxcl13 Recombinant Multiclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cxcl13/CXCL13%2FBCA1+Antibody/pmc12765953-32-0-6
    Average 93 stars, based on 1 article reviews
    rabbit anti cxcl13 recombinant multiclonal antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.

    Journal: Frontiers in Immunology

    Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

    doi: 10.3389/fimmu.2026.1804103

    Figure Lengend Snippet: CXCL13 mRNA expression in PBMCs from patients with Sézary syndrome and other confounding skin diseases. (A) Box-and-whisker plots showing individual CXCL13 ΔCt values in PBMCs from patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS) and healthy donors (HD). ΔCt values were calculated using GAPDH as housekeeping gene. Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. ***p ≤ 0.001; *p ≤ 0.05. (B) Relative CXCL13 expression levels expressed as fold change (RQ) for each disease group relative to HD, calculated using the mean ΔCt value of HD as reference. RQmin and RQmax represent the minimum and maximum relative quantities obtained by adding or subtracting, respectively, the standard deviation of ΔCt values to ΔΔCt.

    Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

    Techniques: Expressing, Whisker Assay, Standard Deviation

    CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.

    Journal: Frontiers in Immunology

    Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

    doi: 10.3389/fimmu.2026.1804103

    Figure Lengend Snippet: CXCL13 immunohistochemical expression in skin biopsies from Sézary syndrome, mycosis fungoides and inflammatory skin diseases. Representative immunohistochemical staining for CXCL13 in skin lesions from patients with Sézary syndrome [SS; (A) ] and mycosis fungoides [MF; (B) ], showing CXCL13 expression in endothelial cells and neoplastic lymphocytes infiltrating the dermis, frequently displaying a dot-like staining pattern. In atopic dermatitis [AD; (C) ], psoriasis [PS; (D) ], eczema [EC; (E) ] and healthy donor skin [HD; (F) ], CXCL13 immunoreactivity is mainly confined to endothelial cells and scattered non-neoplastic lymphocytes. Sections were counterstained with haematoxylin. Original magnification: ×10; inserts ×40.

    Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

    Techniques: Immunohistochemical staining, Expressing, Staining

    Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.

    Journal: Frontiers in Immunology

    Article Title: CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases

    doi: 10.3389/fimmu.2026.1804103

    Figure Lengend Snippet: Plasma CXCL13 levels and diagnostic performance in Sézary syndrome. (A) Box-and-whisker plots showing individual plasma CXCL13 concentrations in patients with Sézary syndrome (SS), mycosis fungoides (MF), atopic dermatitis (AD), psoriasis (PS), eczema (EC) and healthy donors (HD). Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. (B) Plasma CXCL13 concentrations in MF patients stratified according to disease stage at sampling (stage IB/IIA vs . advanced stages IIB and III). Statistical significance was assessed using the Mann–Whitney U test. (C) Receiver operating characteristic (ROC) curve analysis evaluating the ability of plasma CXCL13 to discriminate SS patients from all non-SS individuals (MF, AD, PS, EC and HD). The red cross indicates the selected cut-off value (151.1 pg/mL) maximising sensitivity (87%) and specificity (88%). (D) Box-and-whisker plots showing individual plasma CXCL13 concentrations in SS (right) and non-SS (left) patients. The dotted line indicates the ROC-derived cut-off value. Statistical significance was assessed using the Mann–Whitney U test. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05.

    Article Snippet: Sections were then incubated overnight at 4 °C with a goat polyclonal anti-CXCL13 antibody (AF801; R&D Systems) at a concentration of 2.5 μg/mL in 2% bovine serum albumin (BSA).

    Techniques: Clinical Proteomics, Diagnostic Assay, Whisker Assay, Sampling, MANN-WHITNEY, Derivative Assay